Senores Pharmaceuticals Limited has informed the Exchange regarding corrigendum to the Annual Report of the Company for the financial year 2024-25.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals has issued a corrigendum to its FY 2024-25 Annual Report, which was originally circulated on August 26, 2025. The corrigendum fixes an inadvertent oversight by adding missing disclosure sub-headings on page 71 (Dividend Distribution Policy and Code of Conduct under Other Disclosures), an additional point on page 99, and further points including a Declaration of Code of Conduct on page 100. The 8th AGM is scheduled for September 18, 2025 via video conferencing. The underlying Annual Report figures remain strong: Revenue from Operations at ₹418 Cr (+92% YoY), EBITDA at ₹109 Cr (+148% YoY) with margin expanding 640 bps to 27%, and PAT at ₹58.3 Cr (+78.3% YoY). No financial or business data has been altered; only administrative disclosures were added.
This is a routine procedural correction with no material impact on shareholders or the stock. The added disclosures on dividend policy and code of conduct are standard corporate governance items and do not change any reported numbers or outlook.